 OSLO, Norway--BUSINESS WIRE--- ULTI--Ultimovacs ASA Ultimovacs, ticker ULTI today announced that an abstract on the Companys Phase I trial evaluating its universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab in patients with metastatic malignant melanoma has been accepted for a poster presentation at the American Society of Clinical Oncology ASCO 2021 Annual Meeting to be held virtually Friday, June 4, 2021 through Tuesday, June 8, 2021. The abstract, titled 